cabergoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
ergot alkaloid derivatives	460	81409-90-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cabergoline dostinex galastop cabaser cabaseril	An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. Molecular weight: 451.62 Formula: C26H37N5O2 CLOGP: 4.17 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 71.68 ALOGS: -3.85 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cabergoline
dostinex
galastop
cabaser
cabaseril

An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.

Molecular weight: 451.62
Formula: C26H37N5O2
CLOGP: 4.17
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 71.68
ALOGS: -3.85
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	mg	O
3	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	3 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	65 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Dec. 23, 1996	FDA
Aug. 1, 1999	PMDA	PFIZER JAPAN INC.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood growth hormone increased	180.98	17.41	34	8240	436	63480312
Insulin-like growth factor increased	163.91	17.41	35	8239	884	63479864
Aortic valve incompetence	114.42	17.41	39	8235	5949	63474799
Insulin-like growth factor decreased	105.26	17.41	21	8253	375	63480373
Pulmonary pain	104.63	17.41	32	8242	3458	63477290
Ovarian hyperstimulation syndrome	88.02	17.41	29	8245	3985	63476763
Pituitary tumour	81.89	17.41	20	8254	928	63479820
Blood prolactin increased	75.57	17.41	25	8249	3478	63477270
Amyloid arthropathy	69.77	17.41	16	8258	564	63480184
Needle issue	67.51	17.41	31	8243	10345	63470403
Coronary artery dissection	63.47	17.41	16	8258	846	63479902
Blood prolactin decreased	62.42	17.41	10	8264	45	63480703
Mitral valve incompetence	56.64	17.41	34	8240	19560	63461188
Pituitary haemorrhage	50.41	17.41	9	8265	85	63480663
Empty sella syndrome	50.12	17.41	8	8266	35	63480713
Pituitary tumour benign	46.10	17.41	15	8259	1980	63478768
Inappropriate schedule of product administration	44.46	17.41	61	8213	103904	63376844
Prolactin-producing pituitary tumour	42.40	17.41	8	8266	105	63480643
Acromegaly	39.32	17.41	7	8267	65	63480683
Cardiac valve disease	38.38	17.41	16	8258	4236	63476512
Mediastinal fibrosis	38.23	17.41	6	8268	23	63480725
Compulsive shopping	36.27	17.41	10	8264	749	63479999
Tricuspid valve incompetence	36.22	17.41	23	8251	14598	63466150
Bite	35.77	17.41	9	8265	472	63480276
Diabetes mellitus	33.83	17.41	39	8235	55771	63424977
Pneumocephalus	32.92	17.41	7	8267	173	63480575
Blood pressure increased	32.76	17.41	68	8206	161994	63318754
Cerebrospinal fluid leakage	31.83	17.41	10	8264	1180	63479568
Gambling disorder	31.33	17.41	10	8264	1242	63479506
Injection site mass	31.14	17.41	23	8251	18633	63462115
Cholelithiasis	30.58	17.41	33	8241	43892	63436856
Overweight	30.15	17.41	13	8261	3738	63477010
Hypogonadism	30.08	17.41	6	8268	107	63480641
Urine calcium/creatinine ratio increased	29.72	17.41	6	8268	114	63480634
Hemianopia heteronymous	28.22	17.41	5	8269	45	63480703
Mastitis	27.50	17.41	11	8263	2621	63478127
Abortion spontaneous	26.97	17.41	32	8242	47163	63433585
Neoplasm progression	26.47	17.41	28	8246	36400	63444348
Urethral caruncle	25.35	17.41	5	8269	84	63480664
Delusion	25.12	17.41	17	8257	12000	63468748
Death	24.67	17.41	9	8265	374372	63106376
Kounis syndrome	24.41	17.41	9	8265	1721	63479027
Camptocormia	24.07	17.41	6	8268	303	63480445
Aortic valve sclerosis	23.67	17.41	8	8266	1188	63479560
Body temperature decreased	23.11	17.41	20	8254	20299	63460449
Blood growth hormone abnormal	22.78	17.41	4	8270	34	63480714
Blood parathyroid hormone increased	22.69	17.41	10	8264	3028	63477720
Ovarian rupture	22.29	17.41	4	8270	39	63480709
Toxicity to various agents	22.15	17.41	3	8271	247247	63233501
Infusion related reaction	21.95	17.41	3	8271	245518	63235230
Dopamine dysregulation syndrome	21.84	17.41	5	8269	175	63480573
Obesity	21.72	17.41	23	8251	29929	63450819
Blood thyroid stimulating hormone decreased	21.63	17.41	11	8263	4579	63476169
Chikungunya virus infection	21.49	17.41	5	8269	188	63480560
Hormone level abnormal	21.26	17.41	9	8265	2474	63478274
Injection site pain	21.17	17.41	50	8224	129750	63350998
Application site mass	21.16	17.41	4	8270	53	63480695
Nervousness	21.08	17.41	23	8251	30956	63449792
Panic disorder	20.75	17.41	9	8265	2624	63478124
Nocturia	20.65	17.41	13	8261	8128	63472620
Injection site hypertrophy	20.46	17.41	4	8270	64	63480684
Blood sodium increased	20.43	17.41	9	8265	2723	63478025
Hyperprolactinaemia	20.31	17.41	10	8264	3890	63476858
Memory impairment	20.18	17.41	43	8231	104215	63376533
Hypopituitarism	20.07	17.41	7	8267	1141	63479607
Arteriovenous fistula	19.75	17.41	5	8269	269	63480479
Galactorrhoea	19.71	17.41	10	8264	4145	63476603
Dengue fever	19.60	17.41	6	8268	649	63480099
Neoplasm	19.31	17.41	12	8262	7333	63473415
Pituitary tumour recurrent	19.21	17.41	4	8270	89	63480659
Blood pressure systolic increased	19.03	17.41	27	8247	47370	63433378
Blood gonadotrophin decreased	19.01	17.41	3	8271	12	63480736
Adjacent segment degeneration	19.01	17.41	3	8271	12	63480736
Hypothalamo-pituitary disorder	18.78	17.41	6	8268	747	63480001
Secondary hypogonadism	18.73	17.41	4	8270	101	63480647
Pituitary tumour removal	18.30	17.41	3	8271	16	63480732
Vitamin B12 decreased	18.01	17.41	9	8265	3611	63477137
Mitral valve disease	18.00	17.41	8	8266	2472	63478276
Normal newborn	17.91	17.41	12	8262	8329	63472419
Infection	17.87	17.41	4	8270	229169	63251579
Multiple endocrine neoplasia Type 1	17.86	17.41	3	8271	19	63480729
Mitral valve sclerosis	17.81	17.41	4	8270	128	63480620
Headache	17.81	17.41	142	8132	633099	62847649
Insulin-like growth factor abnormal	17.73	17.41	3	8271	20	63480728

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebrospinal fluid leakage	260.44	21.88	48	5053	488	34951342
Gambling disorder	180.12	21.88	43	5058	1617	34950213
Insulin-like growth factor increased	139.01	21.88	33	5068	1210	34950620
Aortic valve incompetence	103.11	21.88	37	5064	5867	34945963
Pneumocephalus	81.38	21.88	15	5086	152	34951678
Radiation inflammation	80.58	21.88	20	5081	885	34950945
Mitral valve incompetence	78.69	21.88	40	5061	14903	34936927
Visual pathway disorder	75.14	21.88	11	5090	19	34951811
Pulmonary pain	74.58	21.88	20	5081	1204	34950626
Pituitary haemorrhage	72.47	21.88	14	5087	186	34951644
Needle issue	62.42	21.88	26	5075	6139	34945691
Empty sella syndrome	53.14	21.88	9	5092	53	34951777
Secondary hypogonadism	49.78	21.88	11	5090	291	34951539
Blood growth hormone increased	47.03	21.88	11	5090	377	34951453
Cardiac valve disease	45.03	21.88	17	5084	3101	34948729
Jealous delusion	43.94	21.88	10	5091	303	34951527
Neoplasm progression	43.22	21.88	32	5069	23268	34928562
Prolactin-producing pituitary tumour	43.18	21.88	7	5094	30	34951800
Pituitary tumour	42.81	21.88	11	5090	560	34951270
Impulse-control disorder	42.15	21.88	13	5088	1288	34950542
Hormone level abnormal	41.23	21.88	10	5091	401	34951429
Acromegaly	40.80	21.88	7	5094	45	34951785
Hypersexuality	36.34	21.88	12	5089	1481	34950349
Intracranial hypotension	35.36	21.88	8	5093	236	34951594
Tricuspid valve incompetence	34.30	21.88	20	5081	9740	34942090
Cortisol free urine increased	34.02	21.88	5	5096	9	34951821
Pleural effusion	33.82	21.88	50	5051	81496	34870334
Pleural fibrosis	33.22	21.88	11	5090	1369	34950461
Glucose tolerance decreased	31.54	21.88	6	5095	73	34951757
Gambling	31.19	21.88	7	5094	199	34951631
Schizophrenia	31.09	21.88	18	5083	8648	34943182
Arthropathy	30.99	21.88	28	5073	26879	34924951
Lung neoplasm malignant	30.27	21.88	23	5078	17372	34934458
Blood corticotrophin increased	29.84	21.88	6	5095	99	34951731
Injection site erosion	29.56	21.88	6	5095	104	34951726
Injection site pain	29.02	21.88	32	5069	38973	34912857
Death	29.00	21.88	11	5090	398038	34553792
Therapeutic response decreased	28.94	21.88	28	5073	29285	34922545
Knee arthroplasty	28.15	21.88	16	5085	7428	34944402
Priapism	28.12	21.88	14	5087	4980	34946850
Hemianopia	27.06	21.88	8	5093	686	34951144
Autoimmune thyroiditis	26.83	21.88	9	5092	1165	34950665
Borderline personality disorder	26.75	21.88	7	5094	383	34951447
Dopamine dysregulation syndrome	25.66	21.88	7	5094	449	34951381
Carcinoid tumour	24.95	21.88	6	5095	232	34951598
IIIrd nerve paralysis	24.73	21.88	7	5094	515	34951315
Renal haematoma	24.63	21.88	7	5094	522	34951308
Blood prolactin increased	23.27	21.88	9	5092	1751	34950079
Persecutory delusion	23.18	21.88	10	5091	2570	34949260
Oncologic complication	22.70	21.88	6	5095	341	34951489
Aortic valve disease	22.43	21.88	8	5093	1243	34950587

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebrospinal fluid leakage	236.54	15.56	54	11701	1645	79730988
Insulin-like growth factor increased	230.93	15.56	54	11701	1832	79730801
Blood growth hormone increased	178.95	15.56	37	11718	699	79731934
Pulmonary pain	175.89	15.56	52	11703	4421	79728212
Aortic valve incompetence	163.07	15.56	59	11696	9471	79723162
Gambling disorder	156.26	15.56	40	11715	1986	79730647
Pneumocephalus	117.11	15.56	23	11732	331	79732302
Needle issue	114.85	15.56	50	11705	13018	79719615
Pituitary haemorrhage	113.89	15.56	22	11733	289	79732344
Mitral valve incompetence	109.10	15.56	62	11693	28503	79704130
Insulin-like growth factor decreased	89.03	15.56	20	11735	565	79732068
Pituitary tumour	88.74	15.56	23	11732	1199	79731434
Blood prolactin increased	88.43	15.56	30	11725	3981	79728652
Ovarian hyperstimulation syndrome	83.83	15.56	28	11727	3543	79729090
Empty sella syndrome	82.73	15.56	14	11741	81	79732552
Acromegaly	80.68	15.56	14	11741	96	79732537
Radiation inflammation	80.35	15.56	20	11735	885	79731748
Visual pathway disorder	70.25	15.56	12	11743	74	79732559
Amyloid arthropathy	67.81	15.56	16	11739	564	79732069
Tricuspid valve incompetence	65.24	15.56	39	11716	19673	79712960
Cardiac valve disease	60.52	15.56	25	11730	5716	79726917
Prolactin-producing pituitary tumour	59.25	15.56	11	11744	115	79732518
Coronary artery dissection	57.02	15.56	16	11739	1128	79731505
Secondary hypogonadism	52.82	15.56	12	11743	357	79732276
Intracranial hypotension	51.39	15.56	12	11743	404	79732229
Hormone level abnormal	48.19	15.56	16	11739	1986	79730647
Blood pressure increased	46.81	15.56	99	11656	211261	79521372
Neoplasm progression	46.21	15.56	47	11708	51635	79680998
Pituitary tumour benign	44.24	15.56	16	11739	2560	79730073
Diabetes mellitus	44.02	15.56	56	11699	78334	79654299
Toxicity to various agents	42.25	15.56	6	11749	421534	79311099
Death	41.27	15.56	16	11739	566498	79166135
Blood growth hormone abnormal	41.00	15.56	7	11748	43	79732590
Acute kidney injury	40.69	15.56	13	11742	519391	79213242
Knee arthroplasty	39.88	15.56	40	11715	43208	79689425
Dopamine dysregulation syndrome	38.85	15.56	10	11745	507	79732126
Injection site pain	38.73	15.56	69	11686	129769	79602864
Mediastinal fibrosis	38.14	15.56	6	11749	20	79732613
Jealous delusion	38.04	15.56	9	11746	321	79732312
Syndactyly	33.91	15.56	7	11748	131	79732502
Gambling	33.63	15.56	8	11747	292	79732341
Bite	33.57	15.56	9	11746	535	79732098
Obesity	33.33	15.56	33	11722	35092	79697541
Glucose tolerance decreased	31.26	15.56	6	11749	76	79732557
Injection site mass	31.21	15.56	25	11730	20159	79712474
Inappropriate schedule of product administration	31.20	15.56	64	11691	133564	79599069
Hypersexuality	30.98	15.56	11	11744	1669	79730964
Delusion	30.95	15.56	25	11730	20398	79712235
Pituitary enlargement	30.84	15.56	6	11749	82	79732551
Mitral valve disease	30.60	15.56	13	11742	3184	79729449
Pleural fibrosis	30.39	15.56	14	11741	4153	79728480
Aortic valve sclerosis	30.36	15.56	11	11744	1769	79730864
Intentional product misuse	30.22	15.56	52	11703	95113	79637520
Neoplasm	30.06	15.56	18	11737	9098	79723535
Compulsive shopping	29.96	15.56	9	11746	807	79731826
Priapism	29.35	15.56	14	11741	4491	79728142
Cardiomegaly	29.26	15.56	27	11728	26325	79706308
Injection site erosion	27.97	15.56	6	11749	136	79732497
Reversible cerebral vasoconstriction syndrome	27.84	15.56	12	11743	3045	79729588
Urine calcium/creatinine ratio increased	27.72	15.56	6	11749	142	79732491
Visual field defect	27.62	15.56	17	11738	9028	79723605
Body temperature decreased	26.50	15.56	28	11727	32117	79700516
Headache	26.04	15.56	175	11580	653597	79079036
Tricuspid valve disease	25.96	15.56	7	11748	425	79732208
Aortic valve disease	25.83	15.56	10	11745	1931	79730702
Heart rate decreased	25.79	15.56	41	11714	70275	79662358
Carotid aneurysm rupture	25.51	15.56	4	11751	13	79732620
Urethral caruncle	25.32	15.56	5	11750	74	79732559
Hallucination	24.83	15.56	45	11710	85700	79646933
Blood pressure systolic increased	24.48	15.56	39	11716	66947	79665686
Drug abuse	23.86	15.56	65	11690	162626	79570007
Blood prolactin decreased	23.79	15.56	6	11749	280	79732353
Cardiac valve sclerosis	23.37	15.56	5	11750	112	79732521
Impulse-control disorder	23.11	15.56	9	11746	1765	79730868
Oncologic complication	22.75	15.56	6	11749	335	79732298
Ovarian rupture	22.62	15.56	4	11751	31	79732602
Persecutory delusion	22.43	15.56	12	11743	4897	79727736
Blindness	22.12	15.56	24	11731	28359	79704274
Sleep apnoea syndrome	21.97	15.56	27	11728	36451	79696182
Renal haematoma	21.58	15.56	7	11748	808	79731825
Schizophrenia	21.51	15.56	18	11737	15422	79717211
Infusion related reaction	21.42	15.56	4	11751	230233	79502400
Lower respiratory tract infection	21.37	15.56	54	11701	129166	79603467
Mastitis	21.27	15.56	9	11746	2182	79730451
Cholelithiasis	21.11	15.56	32	11723	52632	79680001
Cortisol free urine increased	21.04	15.56	4	11751	48	79732585
Pituitary tumour recurrent	20.88	15.56	5	11750	188	79732445
Lung neoplasm malignant	20.79	15.56	23	11732	27769	79704864
Rheumatoid arthritis	20.78	15.56	3	11752	208467	79524166
Camptocormia	20.62	15.56	6	11749	482	79732151
Sepsis	20.61	15.56	7	11748	269421	79463212
Blood testosterone decreased	20.57	15.56	9	11746	2368	79730265
Drug resistance	20.36	15.56	28	11727	42185	79690448
Hyperprolactinaemia	20.16	15.56	11	11744	4665	79727968
Pneumonia	20.16	15.56	42	11713	660204	79072429
Carcinoid tumour	19.83	15.56	6	11749	551	79732082
Pleural effusion	19.30	15.56	56	11699	145206	79587427
Injection site hypertrophy	19.27	15.56	4	11751	77	79732556
Adenoma benign	19.17	15.56	7	11748	1151	79731482
Mitral valve sclerosis	19.14	15.56	5	11750	269	79732364
IIIrd nerve paralysis	18.97	15.56	7	11748	1186	79731447
Hypothalamo-pituitary disorder	18.96	15.56	7	11748	1187	79731446
Performance enhancing product use	18.89	15.56	4	11751	85	79732548
Arthropathy	18.66	15.56	63	11692	177048	79555585
Adjacent segment degeneration	18.64	15.56	3	11752	12	79732621
Hemianopia heteronymous	18.51	15.56	4	11751	94	79732539
Autoimmune thyroiditis	18.37	15.56	10	11745	4223	79728410
Normal newborn	18.37	15.56	12	11743	7060	79725573
Product dose omission issue	17.82	15.56	78	11677	247459	79485174
Movement disorder	17.76	15.56	21	11734	27238	79705395
Mass	17.67	15.56	17	11738	17455	79715178
Blood cholesterol abnormal	17.62	15.56	9	11746	3341	79729292
Genital pain	17.59	15.56	6	11749	808	79731825
Memory impairment	16.73	15.56	45	11710	111689	79620944
Drug hypersensitivity	16.50	15.56	12	11743	298904	79433729
Hemianopia	16.45	15.56	7	11748	1721	79730912
Tumour compression	16.32	15.56	4	11751	166	79732467
Thyroid mass	16.14	15.56	9	11746	3981	79728652
Treatment failure	15.78	15.56	3	11752	170483	79562150
Cortisol increased	15.74	15.56	5	11750	540	79732093
Blood corticotrophin increased	15.71	15.56	4	11751	194	79732439
Brain neoplasm	15.70	15.56	10	11745	5636	79726997

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G02CB03	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Prolactine inhibitors
ATC	N04BC06	NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopamine agonists
FDA CS	M0007652	Ergolines
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:51065	Dopamine receptor agonist
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018491	Dopamine Agonists
MeSH PA	D018377	Neurotransmitter Agents
FDA EPC	N0000175827	Ergot Derivative

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperprolactinemia	indication	237662005	DOID:12700
Prevention of ovarian hyperstimulation syndrome	indication
Heart valve disorder	contraindication	368009	DOID:4079
Severe pre-eclampsia	contraindication	46764007
Retroperitoneal fibrosis	contraindication	49120005
Fibrosis of lung	contraindication	51615001	DOID:3770
Fibrosis of pericardium	contraindication	194965002
Disease of liver	contraindication	235856003	DOID:409
Breastfeeding (mother)	contraindication	413712001
Hypertensive urgency	contraindication	443482000
Occlusive Vascular Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.83	acidic
pKa2	13.48	acidic
pKa3	7.88	Basic
pKa4	5.97	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	9.20	IUPHAR	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	ANTAGONIST	Ki	7.90	IUPHAR
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	7.70	IUPHAR
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	AGONIST	Ki	8.20	IUPHAR
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	8.85	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	AGONIST	Ki	6.20	IUPHAR
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	ANTAGONIST	Ki	6.50	IUPHAR
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN	ANTAGONIST	Ki	7.10	IUPHAR
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	9.10	IUPHAR
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN	AGONIST	Ki	7.70	IUPHAR
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Ki	6.30	IUPHAR
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	AGONIST	Ki	8.10	IUPHAR
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	ANTAGONIST	Ki	7.70	IUPHAR
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	7.30	IUPHAR
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.78	PDSP
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	AGONIST	Ki	6.70	IUPHAR
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	7.22	PDSP

External reference:

ID	Source
4021014	VUID
N0000148483	NUI
D00987	KEGG_DRUG
134895	RXNORM
C0107994	UMLSCUI
CHEBI:3286	CHEBI
CHEMBL1201087	ChEMBL_ID
D000077465	MESH_DESCRIPTOR_UI
DB00248	DRUGBANK_ID
37	IUPHAR_LIGAND_ID
5860	INN_ID
LL60K9J05T	UNII
54746	PUBCHEM_CID
4317	MMSL
6425	MMSL
73532	MMSL
d04112	MMSL
109139002	SNOMEDCT_US
386979007	SNOMEDCT_US
4021014	VANDF
005446	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5420	TABLET	0.50 mg	ORAL	ANDA	25 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5420	TABLET	0.50 mg	ORAL	ANDA	25 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	23155-823	TABLET	0.50 mg	ORAL	ANDA	11 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	23155-823	TABLET	0.50 mg	ORAL	ANDA	11 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	49884-673	TABLET	0.50 mg	ORAL	ANDA	21 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3157	TABLET	0.50 mg	ORAL	ANDA	25 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3951	TABLET	0.50 mg	ORAL	ANDA	21 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5834	TABLET	0.50 mg	ORAL	ANDA	22 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5834	TABLET	0.50 mg	ORAL	ANDA	22 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6596	TABLET	0.50 mg	ORAL	ANDA	11 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	50742-118	TABLET	0.50 mg	ORAL	ANDA	23 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	59762-1005	TABLET	0.50 mg	ORAL	NDA AUTHORIZED GENERIC	22 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	59762-1005	TABLET	0.50 mg	ORAL	NDA AUTHORIZED GENERIC	22 sections
Cabergoline	HUMAN PRESCRIPTION DRUG LABEL	1	70512-860	TABLET	0.50 mg	ORAL	ANDA	22 sections